Background {#s0005}
==========

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic and international health emergency by the World Health Organization (WHO) [@b0005]. Notably, the obesity pandemic causes at least 2.8 million deaths each year, and no strategy has proven to be effective in reducing its incidence [@b0010], [@b0015]. Finkelstein et al. [@b0020] predict that by 2030, more than 51% of the population worldwide could suffer from obesity.

Obesity causes a chronic low-grade inflammatory state, and this inflammation has been associated with different chronic diseases, such as type 2 diabetes, arterial hypertension, cardiovascular diseases, metabolic syndrome, non-alcoholic liver steatosis, non-allergic asthma, autoimmune diseases and certain types of cancer [@b0025].

Some diseases associated with obesity, such as diabetes, arterial hypertension and cardiovascular diseases, have been well identified as risk factors for death related to COVID-19. Zhou et al. [@b0030] reported that compared with patients with COVID-19 alone, patients with COVID-19 and coronary heart disease have a probability of death 21-fold higher (odds ratio \[OR\] 21.4; 95% CI: 4.64--98.76, p \< 0.0001), those with COVID-19 and diabetes have an almost 3-fold higher probability of death (OR 2.85; 95% CI: 1.35--6.05, p = 0.0062) and those with arterial hypertension have a 3 times higher chance of dying (OR 3.05; 95% CI: 1.57--5.92, p = 0.0010); however, that study, conducted in the city of Wuhan, China, does not specify whether these patients also suffered from obesity.

Petrilli et al. [@b0035] conducted a study in New York City (US) with 4,103 patients with COVID-19 and found that compared with patients with a body mass index (BMI) \< 30 kg/m^2^, patients with a body mass index (BMI) of 30--40 kg/m^2^ were 4.26 times more likely to be hospitalized (OR 4.26; 95% CI: 3.5--5.2, p \< 0.001) and those with a BMI \> 40 kg/m^2^ were 6.2 times more likely to be hospitalized (OR 6.2; 95% CI: 4.21--9.25, p \< 0.001). In that study, the ORs were adjusted for age, sex, race, chronic diseases and smoking, and it was found that obesity was an independent predictor for hospitalization due to COVID-19.

Recent data from New York City [@b0040] have shown that patients under 60 years of age with a BMI between 30--34 kg/m^2^ were almost twice as likely to be admitted to the intensive care unit (ICU) (OR 1.8; 95% CI: 1.20--2.7, p = 0.006) than were patients with a BMI \< 30 kg/m^2^. It was also observed that the higher the BMI, the higher the probability was: patients with a BMI \> 35 kg/m^2^ were 3.6 times more likely to be admitted to the ICU (OR 3.6; 95% CI: 2.5--5.3, p \< 0.0001).

A study conducted in France [@b0045] showed that the odds may be even higher, as patients with a BMI \> 35 kg/m^2^ were 7 times more likely to require invasive mechanical ventilation (IMV) than were patients with a BMI \< 25 kg/m^2^ (OR 7.36; 95% CI: 1.63--33.14, p = 0.021). Interestingly the OR was adjusted for age, sex, diabetes, hypertension and dyslipidaemias, indicating that obesity itself was an independent risk factor for IMV.

A study by Zheng et al. [@b0050] showed that patients with metabolic associated fatty liver disease with obesity were 6 times more likely to present with severe COVID-19 than were patients with metabolic associated fatty liver disease without obesity (OR 6.32; 95% CI: 1.16--34.54, p = 0.033). The OR was adjusted for age, sex, smoking, type 2 diabetes, hypertension and dyslipidaemia. The most interesting finding of that study was that obesity was a predictor of COVID-19 severity, regardless of the presence of metabolic associated fatty liver disease.

These epidemiological data are very alarming and are a concern for public health, particularly in countries where there is a high rate of obesity. Patients with obesity and COVID-19 could overwhelm ICU capacity, consequently collapsing the health system.

It is well documented that acute respiratory distress syndrome (ARDS) is one of the main causes of death related to COVID-19 and that ARDS is triggered by a cytokine storm that directly damages the respiratory epithelium, liver, heart and kidney [@b0030], [@b0055].

It is important to highlight that interleukins that cause the chronic low-grade inflammatory state of obesity, such as interleukin (IL)-1β, IL-6, IL-17A, tumour necrosis factor alpha (TNF-α) and monocyte chemoattractant peptide (MCP)-1, also play very important roles in ADRS-related lung damage in patients with COVID-19. Additionally, the interleukins that cause lung damage in a model of obesity and asthma, such as TNF-α, IL-6, IL-8, IL-17A, regulated on activation, normal T cell expressed and secreted (RANTES), granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), vascular cell adhesion molecule-1 (VCAM-1) and vascular endothelial growth factor (VEGF), are the same that cause lung damage associated with COVID-19. Therefore, it is assumed that obesity is associated with an immune state favourable to a cytokine storm, ARDS, multiple organ failure and death [@b0025], [@b0060], [@b0065].

Huang et al. [@b0065] showed that the levels of cytokines such as IL-1β, IL-6, IL-8, IL-17, G-CSF, GM-CSF, interferon γ (IFN-γ), MCP-1, TNF-α and VEFG are higher in patients with COVID-19 than in healthy adults. In that same study, it was observed that plasma concentrations of MCP-1 and TNF-α were high in patients with COVID-19 who were admitted to the ICU. Similarly, Chen et al. [@b0070] reported that patients with severe COVID-19 have high concentrations of IL-6 and TNF-α. As we can see, the cytokine profile in COVID-19 is predominantly Th1-Th17, similar to obesity.

Obesity is associated with an immune state favourable to a cytokine storm caused by COVID-19 {#s0010}
============================================================================================

The main source of IL-17A in obesity is Th17 lymphocytes and group 3 innate lymphoid cells (ILC3), and the main source of IL-1β, IL-6, IL-15 and TNF-α in obesity is type 1 macrophages (M1) located in visceral adipose tissue. IL-1β, IL-6 and IL-15 are essential for naïve CD4^+^ T cells to differentiate into Th17 lymphocytes and become activated [@b0075], [@b0080], [@b0085]. ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Obesity is associated with an immune state favourable to a cytokine storm caused by COVID-19. Obesity causes chronic low-grade inflammation with increased tumour necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6 and IL-15 levels. IL-1β, IL-6 and IL-15 are essential for naïve CD4^+^ T cells to differentiate into Th17 lymphocytes. IL-6 stimulates retinoid-related orphan receptor C (*RORC*) gene expression and consequently *IL17A* gene expression*.* IL-17A stimulates type 1 macrophage (M1), which in turn responds with the increased synthesis of IL-1β, IL-6 and IL-15, and these cytokines activate more Th17 lymphocytes. There is positive feedback between M1 macrophages and Th17 cells. Moreover, acetyl-CoA carboxylase 1 (ACC1), a key enzyme for the synthesis of fatty acids, is upregulated in obesity, and fatty acids directly activate RORC and, as a result, *IL17A* gene expression*.* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is captured and processed by macrophages, dendritic cells and monocytes; these cells, when processing and presenting the antigen to naïve CD4^+^ T lymphocytes, produce large amounts of IL-1β, IL-6 and TNF-α, which activate more Th17 lymphocytes. Thus, there is a positive feedback loop between the low-grade inflammation of obesity and the immunology of COVID-19. Finally, all these immunological events culminate in higher concentrations of IL-17A and TNF-α and, consequently, greater lung damage and death.

IL-6 is elevated in obese patients, and its main source is M1 macrophages. Moreover, IL-6 plays an important role in the differentiation of Th17 lymphocytes; it binds to signal transducer and activator of transcription 3 (STAT3), and this signal activator binds directly to the chromatin of Th17 lymphocytes and activates the gene expression of retinoid-related orphan receptor C (*RORC*). RORC forms a complex with histone acetyltransferase p300 coactivator; this complex binds to the chromatin of Th17 lymphocytes and stimulates the expression of *IL-17A* [@b0090], [@b0095] ([Fig. 1](#f0005){ref-type="fig"}).

Apart from this, IL-17A stimulates M1 macrophages, which respond with the increased synthesis of IL-1β, IL-6, IL-15 and TNF-α, which subsequently activate more Th17 lymphocytes. Therefore, there is a positive immunological feedback loop between M1 macrophages and Th17 lymphocytes; for this reason, a Th1-Th17 immune profile predominates in obesity with an increase in serum concentrations of IL-17A and TNF-α [@b0025], [@b0085] ([Fig. 1](#f0005){ref-type="fig"}).

However, IL-6 is not the only pathway through which Th17 lymphocytes are activated. Endo et al. [@b0100] described a metabolic pathway mediated by acetyl-CoA carboxylase 1 (ACC1), a key enzyme for the synthesis of monounsaturated fatty acids, which directly activate RORC as a dependent ligand and consequently stimulate the gene expression of *IL17A.* In patients with obesity, the expression of ACC1 is upregulated; therefore, the synthesis and serum concentrations of monounsaturated fatty acids will be higher, and as a result, the concentrations of IL-17A will be higher as well ([Fig. 1](#f0005){ref-type="fig"}).

The N protein of SARS-CoV is a potent inducer of IL-6. SARS-CoV-2 is captured and processed by macrophages, dendritic cells and monocytes in the respiratory and intestinal epithelia. These cells, when processing and presenting antigen to naïve CD4^+^ T lymphocytes, produce large amounts of IL-1β, IL-6, MCP-1 and TNF-α and, as a result, activate more Th17 lymphocytes. This may explain why patients with ARDS from COVID-19 have a greater number of Th17 lymphocytes in peripheral blood and therefore higher concentrations of IL-17A and TNF-α [@b0055], [@b0060], [@b0065], [@b0105], [@b0110]. As we can see, there is a positive feedback loop between the low-grade inflammation of obesity and the immunology of COVID-19. Finally, all these immunological events culminate in higher concentrations of IL-17A and TNF-α and, consequently, greater lung damage and death. ([Fig. 1](#f0005){ref-type="fig"}).

How may IL-17A and TNF-α cause damage to the respiratory epithelium in patients with COVID-19 and obesity? {#s0015}
==========================================================================================================

TNF-α causes bronchial hyperreactivity, a decrease in the calibre of the airway and significant neutrophilia in the respiratory epithelium [@b0115]. Additionally, TNF-α directly damages the respiratory epithelium, which responds by producing mucin and releasing inflammatory cytokines such as IL-8, GM-CSF, RANTES and intercellular adhesion molecules (ICAMs) [@b0120].

Moreover, TNF-α induces the release of matrix metalloproteinase-9 (MMP-9) by neutrophils and, as a result, stimulates the production of glycosaminoglycans by pulmonary fibroblasts [@b0125]. Apart from this, TNF-α directly stimulates the synthesis of collagen by myofibroblasts and fibroblasts; all these events end in irreversible damage via pulmonary fibrosis [@b0125], [@b0130], [@b0135], [@b0140].

IL-17A acts directly on smooth muscle and on the respiratory epithelium, causing bronchial hyperreactivity. Its main role is the recruitment of neutrophils via IL-8, IL-6, IL-11, GM-CSF and G-CSF induction. These inflammatory cytokines are released by the respiratory epithelium, smooth muscle cells and fibroblasts. Likewise, IL-17A increases the elastases and myeloperoxidases contained in the granules of neutrophils [@b0145], [@b0150].

Neutrophilia in COVID-19 is associated with poor prognosis. Chen et al. [@b0070] reported that patients with severe COVID-19 had a greater number of neutrophils in peripheral blood than did patients with moderate disease (6.9 (interquartile range \[IQR\]: 4.9--9.1) vs 2.7 (IQR: 2.1--3.7) ^×^ 10^9^/L p = 0.002). Remarkably, Huang et al. [@b0065] found similar data; patients who required admission to the ICU had a greater number of neutrophils in peripheral blood than did patients not admitted to the ICU (10.6 (IQR: 5.0--11.8) vs 4.4 (IQR: 2.0-- 6.1) ^×^ 10^9^/L p = 0.00069).

TNF-α and IL-17A stimulate the synthesis of IL-8 by the respiratory epithelium; this interleukin is a potent chemotactic of neutrophils in the lung [@b0155]. Neutrophilia in the respiratory epithelium is associated with severity and death in respiratory diseases such as asthma [@b0160], [@b0165], [@b0170], [@b0175] and severe lung damage in influenza pneumonitis [@b0180].

An in vitro study by Laan et al. [@b0185] showed that IL-17A induced the release of IL-8 by the respiratory epithelium. Pelletier et al. [@b0190] reported that neutrophils induced chemotaxis of Th17 lymphocytes via the CCL2 and CCL20 chemokines.

Laan et al. [@b0195] showed in in vitro experiments that TNF-α and IL-17 potentiated the release of higher concentrations of IL-8 from the respiratory epithelium than did IL-17 or TNF-α individually. In an in vitro experiment, Jones et al. [@b0200] incubated respiratory epithelial cells with IL-17 for 48 h and demonstrated the synthesis and stimulation of IL-8 and G-CSF gene expression. Another important finding was that IL-17 synergistically improved the release of IL-8 and G-CSF induced by TNF-α in respiratory epithelial cells.

Neutrophilia in sputum is associated with obesity. Scott et al. [@b0205] found that in women with obesity and asthma, the percentage of neutrophils in sputum was positively associated with BMI (β = 1.015, 95% CI 0.258--1.772; p = 0.009) and that the proportion of neutrophilia in sputum (neutrophils ≥ 61%) was higher in women with obesity and asthma than in women with asthma without obesity (42.9% vs 16.2%, p = 0.017).

Marijsse et al. [@b0210] reported similar findings. They showed that adults with asthma and obesity had a higher proportion of neutrophils in sputum than did adults with asthma without obesity (66.2% vs 25%, p = 0.02).

Given the above, it can be inferred that the inflammatory pathway of TNF-α and IL-17 is a common pathway for both obesity and COVID-19, as both interleukins are associated with neutrophilia in the respiratory epithelium and, consequently, severe lung damage and death.

Analysis {#s0020}
========

Imagine the scenario of a patient with obesity, whose biological characteristics include elevated levels of proinflammatory cytokines such as IL-1β, IL-6, IL-15, IL-17A and TNF-α and who unfortunately became infected with SARS -CoV-2. It is logical to assume that this patient will have a greater probability of presenting with a cytokine storm due to both inflammatory conditions and, consequently, severe lung damage, multiple organ failure and a poor survival prognosis.

IL-6 is a good prognostic indicator for mortality in patients with COVID-19. Zhou et al. [@b0030] showed that plasma concentrations of IL-6 were higher in patients who died from COVID-19 than those in survivors (11.0 pg/ml (IQR: 7.5--14.4) vs. 6.3 pg/ml (IQR: 5.0--7.9) p \< 0.0001). Interestingly, Ruan et al. [@b0215] also reported very similar findings (11.4 ± 8.5 pg/ml vs 6.8 ± 3.61 pg/ml, p \< 0.001).

A situation that worries doctors in the emergency room and ICU is a cytokine storm as a cause of ARDS, lung damage and death. What immunological characteristics prior to COVID-19 are present in patients with obesity who develop cytokine storms and consequently ARDS, multiple organ failure and death, and what immunological characteristics are present in patients with obesity with COVID-19 who do not develop ARDS and have milder disease? Given the need to make the best clinical decisions for this vulnerable group of patients, we formulated the following hypothesis.

Hypothesis {#s0025}
==========

The serum concentrations of TNF-α and IL-17A are more elevated in patients with COVID-19 and obesity than in patients with COVID-19 without obesity, and the former, consequently, are more likely to develop ARDS and death.

Patients with COVID-19 and obesity who develop ARDS will have higher serum concentrations of TNF-α and IL-17A than those in patients without ARDS. Last, patients with COVID-19 and obesity who died will have higher serum concentrations of TNF-α and IL-17A than those in survivors.

The best design to test our hypothesis is an incipient cohort study, initiating all patients at the same early COVID-19 disease stage, confirmed by a diagnostic RT-PCR test. Serum concentrations of TNF-α and IL-17A will be measured at the beginning of the study and at each established time point. Patients will be followed over time to determine who develops ARDS and who die. A careful analysis of the dynamics of TNF-α and IL-17A concentrations at each time point and for each group of patients will be performed; this analysis will include Kaplan-Meier survival analysis, a Cox\'s proportional hazards regression model adjusted for confounding variables and, last, a receiver-operating characteristic analysis to evaluate accuracy and establish a cut-off point for each cytokine.

Discussion and future perspectives {#s0030}
==================================

Although IL-6 is a good prognostic indicator of COVID-19 severity and COVID-19-related death and seems to be a good therapeutic target for this disease, there is no suitable biomarker for ARDS and mortality or to serve as a therapeutic target for patients with COVID-19 and obesity [@b0030], [@b0215].

It is important to emphasize that the synthesis of IL-17A does not depend solely on IL-6. There is another mechanism mediated by ACC1 and monounsaturated acid acids, which are increased in obesity, and for this reason, this vulnerable group of patients should be considered individually [@b0100].

At present, approximately 15 therapeutic interventions for COVID-19 have been reported, but none has focused on TNF-α and IL-17A. Blocking the biology of TNF-α and IL-17A in their target organs would be a good option as an anti-inflammatory treatment [@b0220], [@b0225].

Wu et al. [@b0230] showed in a murine model that fedratinib, a JAK2 inhibitor, may be a potential therapeutic option for inhibiting IL-17A synthesis in patients with COVID-19. The immunobiology of IL-17A and TNF-α opens a fascinating new field of research for COVID-19.
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